Inactive Instrument

Gyroscope Therapeutics Holdings plc

Equities

VISN

US40382N1037

Biotechnology & Medical Research

Gyroscope Therapeutics Holdings Limited Auditor Raises 'Going Concern' Doubt

January 10, 2021

Gyroscope Therapeutics Holdings Limited filed its DRS on Jan 11, 2021 for the period ending Jan 31, 2020. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Gyroscope Therapeutics Holdings plc

Gyroscope Therapeutics Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-22	CI
Novartis AG acquired Gyroscope Therapeutics Holdings plc on February 18, 2022	22-02-17	CI
Syncona Shares Rise After Novartis Agrees to Buy Portfolio Company	21-12-22	DJ
Novartis to Acquire Gyroscope Therapeutics for Up to $1.5 Billion	21-12-22	DJ
Novartis AG signed an agreement to acquire Gyroscope Therapeutics Holdings plc for £1.1 billion.	21-12-21	CI
Syncona Says Sanofi to Invest up to $60 Million in Gyroscope Therapeutics	21-11-08	DJ
Gyroscope Therapeutics Holdings plc announced that it expects to receive £44.5 million in funding from Sanofi Ventures	21-11-07	CI
Gyroscope Therapeutics Holdings plc Announces Presentation of Positive Interim Phase I/II Data for Investigational Gene Therapy GT005 at Retina Society Annual Scientific Meeting	21-09-30	CI
Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medical Research Institute to Develop Novel Gene Therapy Capsids	21-06-22	CI
Gyroscope Therapeutics Holdings plc has withdrawn its IPO in the amount of $148.5 million.	21-05-07	CI
Gyroscope Therapeutics Holdings plc has filed an IPO in the amount of $100 million.	21-04-16	CI
Gyroscope Therapeutics Holdings Limited Auditor Raises 'Going Concern' Doubt	21-01-10	CI
Gyroscope Therapeutics Limited acquired Orbit Biomedical Inc. from Syncona Portfolio Ltd and other shareholders.	19-04-10	CI

Chart Gyroscope Therapeutics Holdings plc

Duration

Period

Chart Gyroscope Therapeutics Holdings plc

More charts

Company Profile

Gyroscope Therapeutics Holdings plc, formerly Gyroscope Therapeutics Holdings Limited, is a clinical-stage gene therapy company. The Company develop gene therapy beyond rare diseases. It offers therapies to treat diseases of the eye that cause vision loss and blindness. The Company's investigational gene therapy, GT005, is in Phase II clinical trials for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a cause of blindness. The Company develops a pipeline of recombinant adeno-associated virus (rAAV), vector-based gene therapy candidates targeting genetic variants in the pathway to be key drivers of AMD. Its gene therapies are designed as one-time treatments. The Company's lead programs, GT005 and GT011, focus on two key targets such as Complement Factor I (CFI) and factor H like-1 (FHL1), a variant of Complement Factor H (CFH). Its gene therapy, GT005, is designed to restore balance to a system by production of CFI, a regulatory protein.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+47.81%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research